Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment

15Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal evolution of RASs in twelve participants with early acute HCV infections. Full-genome deep sequences were analysed for changes in RAS frequency within NS3, NS5A and NS5B-coding regions over the course of the infection. Emergence of RASs relevant only to the polymerase non-nucleoside inhibitors (NNI) was detected, and these lay within CD8+ T-cell epitopes. Conversely, the loss of NNI RASs over time appeared likely to be driven by viral fitness constraints. These results highlight the importance of monitoring CD8+ T cell epitope-associated RASs in populations with dominant HLA types.

Cite

CITATION STYLE

APA

Eltahla, A. A., Leung, P., Pirozyan, M. R., Rodrigo, C., Grebely, J., Applegate, T., … Bull, R. A. (2017). Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. Scientific Reports, 7. https://doi.org/10.1038/srep41719

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free